Stock listing

NYSE:ADCT ADC Therapeutics SA Stock

Home listing (NYSE) of ADC Therapeutics SA

Follow ADC Therapeutics SA into a list and get an email when it puts out news.

Share price · NYSE:ADCT

$1.44 USD +0.04 (+2.9%)

Close on Oct 19, 2026

Past year -66.4% · daily closes, Oct 20, 2025 – Oct 19, 2026, adjusted for splits
Day range
$1.39 – $1.49 USDOct 19, 2026
Volume
571,057 sharesOct 19, 2026
Market value
$183.8M USDAt the close on Oct 19, 2026 · price × 127.7M shares outstanding
52-week range
$0.78 – $4.98 USDLowest and highest trades, Oct 20, 2025 – Oct 19, 2026
ADC Therapeutics SA logo
Ticker
NYSE:ADCT
Asset type
Stock
Exchange
NYSE
Currency
USD

What changed lately

Calls

Replays

  • ADC Therapeutics (NYSE:ADCT) Q2 2026 Earnings Call

    Thu, Aug 13, 2026 · 8:30 AM ET

    Watch Transcript

  • ADC Therapeutics (NYSE:ADCT) Q1 2026 Earnings Call

    Mon, May 04, 2026 · 8:30 AM ET

    Watch Transcript

  • ADC Therapeutics (NYSE:ADCT) Q4 2025 Earnings Call

    Tue, Mar 10, 2026 · 8:30 AM ET

    Watch Transcript

Latest news

ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements

Oct 8, 2026

ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Sep 3, 2026

ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates

Aug 13, 2026

ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026

Aug 6, 2026

ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial

Jun 30, 2026

ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities

Jun 24, 2026

ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jun 3, 2026

ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

May 4, 2026

ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026

Apr 27, 2026

ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

Mar 10, 2026

All ADC Therapeutics SA news

Financings

  • Private placement of common shares and pre-funded warrants

    Oct 8, 2026

    Announced: US$86.6M · US$1.42 a share · Jefferies +2

    Dealers: Jefferies, Guggenheim Securities, Cantor

    Buyers: Bain Capital Life Sciences; Redmile; TCGX; Nantahala Capital

    Use of proceeds: Fund ZYNLONTA pipeline studies including Phase 3 trials in DLBCL and MZL, strengthen the balance sheet, working capital and general corporate purposes

    Announced Oct 8, 2026

Read by 6ix AI from the company's releases

Decks

ADC Therapeutics SA on 6ix

News releases
22 in the last 12 months · 39 in all · newest Oct 8, 2026 · oldest 2025
Calls
25 calls with a replay · 25 with a transcript · latest Aug 13, 2026
Decks
36 decks · latest Aug 13, 2026

Where ADC Therapeutics SA is listed

ListingExchangeCountryCurrency
NYSE:ADCT · Home listing · This pageNYSEUnited StatesUSD
BOATS:ADCTBOATSUnited StatesUSD

Log in to ask 6ix AI your own questions about ADC Therapeutics SA.